Appearing in The Lancet HIV: We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
The Case For an HIV Cure and How to Get There
Viewpoint appearing in The Lancet HIV
Including Pregnant and Breastfeeding People in Trials of Novel LAED PrEP Agents
Perspective from sub-Saharan Africa community stakeholders
This paper describes how community consultation based in the principles of GPP led to researchers gaining an enhanced understanding of their community’s strongly held views and concerns about PrEP for pregnant and lactating people, and whether and how to include of those people in PrEP research.
COMPASS Africa Newsletter (February 2023)
Year End Newsletter
In this issue: five end of the year SPARC stories, eight topline findings from the coalition health score card, in-country strategy labs and the all COMPASS strategy lab.
Re: Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection
AVAC submits comment and response to the United States Preventative Services Task Force (USPSTF) Draft Recommendation statement for PrEP. The USPSTF recommended an “A” Grade for PrEP that includes CAB for PrEP.
Correlations between Oral Pre-Exposure Prophylaxis (PrEP) Initiations and Policies that Enable the Use of PrEP to Address HIV Globally
This article from PLoS Global Public Health presents the results of an analysis examining whether policies enabling broad PrEP eligibility, HIV self-testing, and lowered age of consent to HIV testing and treatment services are correlated with PrEP uptake.
AVAC Comments to FDA in Support of PrEP Approval
Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.
Future Prospects for New Vaccines Against Sexually Transmitted Infections
This review provides an update on the need, development status, and important next steps for advancing development of vaccines against sexually transmitted infections (STIs), including herpes simplex virus (HSV), Neisseria gonorrhoeae (gonorrhea), Chlamydia trachomatis (chlamydia), and Treponema pallidum (syphilis).
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
The results of HPTN 083, a trial evaluating the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW), in the New England Journal of Medicine.
Enhancing HIV Prevention with Injectable Preexposure Prophylaxis
Quarraisha Abdool Karim, Ph.D. writes about the results of HPTN 083 and the implications of long-acting injectable of PrEP with cabotegravir in the New England Journal of Medicine.
Hormonal Contraceptive Methods and HIV: Research gaps and programmatic priorities
This article in Contraception summarizes key findings and conclusions from a December 2015 meeting convened by WHO on the research agenda for hormonal contraception and HIV.